{
    "ticker": "OBDE",
    "name": "Obsidian Therapeutics, Inc.",
    "description": "Obsidian Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies utilizing advanced gene and cell engineering technologies. Founded in 2015, the company is dedicated to harnessing the power of synthetic biology to create next-generation cell therapies. Obsidian's proprietary technology platform enables the precise control of gene expression in immune cells, which has the potential to revolutionize the treatment of various diseases, including cancer and autoimmune disorders. The company aims to develop therapies that can selectively activate or deactivate genes in response to specific signals, allowing for highly targeted and personalized treatment options. With a robust pipeline of product candidates, including engineered T cells and other cellular therapies, Obsidian is poised to make significant contributions to the field of immunotherapy. The company is committed to advancing science and improving patient outcomes through its innovative approach to medicine and ongoing research initiatives.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.obsidiantx.com",
    "ceo": "Paul Wiggins",
    "social_media": {
        "twitter": "https://twitter.com/ObsidianTx",
        "linkedin": "https://www.linkedin.com/company/obsidian-therapeutics/"
    },
    "investor_relations": "https://investors.obsidiantx.com",
    "key_executives": [
        {
            "name": "Paul Wiggins",
            "position": "CEO"
        },
        {
            "name": "Lynn Seely",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapy",
            "products": [
                "Engineered T Cells"
            ]
        }
    ],
    "seo": {
        "meta_title": "Obsidian Therapeutics, Inc. | Innovating Cell Therapies",
        "meta_description": "Explore Obsidian Therapeutics, Inc., a leader in advanced gene and cell engineering technologies, dedicated to developing innovative therapies for cancer and autoimmune diseases.",
        "keywords": [
            "Obsidian Therapeutics",
            "Cell Therapy",
            "Gene Engineering",
            "Immunotherapy",
            "Biotechnology",
            "Cancer Treatment"
        ]
    },
    "faq": [
        {
            "question": "What does Obsidian Therapeutics focus on?",
            "answer": "Obsidian Therapeutics focuses on developing innovative therapies using advanced gene and cell engineering technologies."
        },
        {
            "question": "Who is the CEO of Obsidian Therapeutics?",
            "answer": "Paul Wiggins is the CEO of Obsidian Therapeutics, Inc."
        },
        {
            "question": "Where is Obsidian Therapeutics headquartered?",
            "answer": "Obsidian Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are the main products of Obsidian Therapeutics?",
            "answer": "Obsidian Therapeutics's main products include engineered T cells and other cellular therapies."
        },
        {
            "question": "When was Obsidian Therapeutics founded?",
            "answer": "Obsidian Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "NTLA",
        "ZGEN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ]
}